| Migraine Disorders
Aimovig vs Zavzpret
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Aimovig vs Zavzpret with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZavzpret has a higher rate of injection site reactions vs Aimovig based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zavzpret but not Aimovig, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aimovig
Zavzpret
At A Glance
SC injection
Once monthly
CGRP receptor antagonist
Intranasal
As needed
CGRP receptor antagonist
Indications
- Migraine Disorders
- Migraine Disorders
Dosing
Migraine Disorders 70 mg SC once monthly; some patients may benefit from 140 mg SC once monthly.
Migraine Disorders 10 mg as a single spray in one nostril as needed; maximum 10 mg (one spray) per 24-hour period; safety of treating more than 8 migraines in a 30-day period has not been established.
Contraindications
- Serious hypersensitivity to erenumab-aooe or any excipient (reactions have included anaphylaxis and angioedema)
- History of hypersensitivity reaction to zavegepant or any component of ZAVZPRET, including anaphylaxis
Adverse Reactions
Most common (>=3%) Injection site reactions, constipation
Serious Hypersensitivity reactions, constipation with serious complications, hypertension, Raynaud's phenomenon
Postmarketing Hypersensitivity reactions (rash, angioedema, anaphylaxis), constipation with serious complications, oral mucosal ulceration, rash, alopecia, hypertension, Raynaud's phenomenon
Most common (>=2%) Taste disorders (dysgeusia, ageusia), nausea, nasal discomfort, vomiting
Serious Hypersensitivity including facial swelling and urticaria (less than 1%)
Postmarketing Hypersensitivity (anaphylaxis), hypertension, Raynaud's phenomenon
Pharmacology
CGRP receptor antagonist; human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function.
Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it blocks CGRP receptor signaling implicated in migraine pathophysiology.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aimovig
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (1/12)
Zavzpret
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Aimovig
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (1/8)
Zavzpret
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Aimovig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Zavzpret
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/momo
Aimovig CoPay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availablePAF Co-Pay Relief: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AimovigView full Aimovig profile
ZavzpretView full Zavzpret profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.